Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Biree Andemariam

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Pediatric Research|June 4, 2013
Transgenic sickle cell disease mice have high mortality and dysregulated immune responses after vaccinationSteven M Szczepanek, Eric R Secor, Sonali J Bracken, et al.
Leukemia & Lymphoma|January 24, 2012
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphomaRebecca L Elstrom, Biree Andemariam, Peter Martin, et al.
British Journal of Cancer|March 21, 2019
Serious adverse events in African-American cancer patients with sickle cell trait and inherited haemoglobinopathies in a SEER-Medicare claims cohortJessica R Hoag, Biree Andemariam, Xiaoyan Wang, et al.
Vaccine|June 20, 2026
Half a century of pneumococcal vaccination in sickle cell disease: Are we winning the battle or losing immunity?Sumit Jamwal, Britney Omene, Abhishek Giri, et al.
American Journal of Hematology|April 26, 2022
Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: A comparative analysis of high- and low- to middle-income countries for the international Sickle Cell World Assessment SurveyIfeyinwa Osunkwo, John James, Fuad El-Rassi, et al.
The American Journal of Pathology|September 25, 2012
Splenic morphological changes are accompanied by altered baseline immunity in a mouse model of sickle-cell diseaseSteven M Szczepanek, Jeffrey T McNamara, Eric R Secor, et al.
Pharmacoeconomics|April 29, 2024
Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United StatesWilliam L Herring, Meghan E Gallagher, Nirmish Shah, et al.
Plos One|February 25, 2016
Poor Long-Term Efficacy of Prevnar-13 in Sickle Cell Disease Mice Is Associated with an Inability to Sustain Pneumococcal-Specific Antibody TitersSteven M Szczepanek, Sean Roberts, Kara Rogers, et al.
Blood Advances|February 17, 2026
Safety and effectiveness of voxelotor in individuals with sickle cell disease in the RETRO and PROSPECT US registriesBiree Andemariam, Nirmish Shah, William B Ershler, et al.
Leukemia & Lymphoma|April 10, 2008
FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphomaSarah C Rutherford, Biree Andemariam, Shibu M Philips, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Pediatric Research|June 4, 2013
Transgenic sickle cell disease mice have high mortality and dysregulated immune responses after vaccinationSteven M Szczepanek, Eric R Secor, Sonali J Bracken, et al.
Leukemia & Lymphoma|January 24, 2012
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphomaRebecca L Elstrom, Biree Andemariam, Peter Martin, et al.
British Journal of Cancer|March 21, 2019
Serious adverse events in African-American cancer patients with sickle cell trait and inherited haemoglobinopathies in a SEER-Medicare claims cohortJessica R Hoag, Biree Andemariam, Xiaoyan Wang, et al.
Vaccine|June 20, 2026
Half a century of pneumococcal vaccination in sickle cell disease: Are we winning the battle or losing immunity?Sumit Jamwal, Britney Omene, Abhishek Giri, et al.
American Journal of Hematology|April 26, 2022
Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: A comparative analysis of high- and low- to middle-income countries for the international Sickle Cell World Assessment SurveyIfeyinwa Osunkwo, John James, Fuad El-Rassi, et al.
The American Journal of Pathology|September 25, 2012
Splenic morphological changes are accompanied by altered baseline immunity in a mouse model of sickle-cell diseaseSteven M Szczepanek, Jeffrey T McNamara, Eric R Secor, et al.
Pharmacoeconomics|April 29, 2024
Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United StatesWilliam L Herring, Meghan E Gallagher, Nirmish Shah, et al.
Plos One|February 25, 2016
Poor Long-Term Efficacy of Prevnar-13 in Sickle Cell Disease Mice Is Associated with an Inability to Sustain Pneumococcal-Specific Antibody TitersSteven M Szczepanek, Sean Roberts, Kara Rogers, et al.
Blood Advances|February 17, 2026
Safety and effectiveness of voxelotor in individuals with sickle cell disease in the RETRO and PROSPECT US registriesBiree Andemariam, Nirmish Shah, William B Ershler, et al.
Leukemia & Lymphoma|April 10, 2008
FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphomaSarah C Rutherford, Biree Andemariam, Shibu M Philips, et al.
Pageof 7